4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidyl decanoate
![4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidyl decanoate Structure](https://image.chemsrc.com/caspic/132/74050-97-8.png)
4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidyl decanoate structure
|
Common Name | 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidyl decanoate | ||
|---|---|---|---|---|
| CAS Number | 74050-97-8 | Molecular Weight | 530.11400 | |
| Density | 1.14 g/cm3 | Boiling Point | 615.5ºC at 760 mmHg | |
| Molecular Formula | C31H41ClFNO3 | Melting Point | 326.1ºC | |
| MSDS | N/A | Flash Point | 326.1ºC | |
|
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
JAMA 311(19) , 1978-87, (2014) Long-acting injectable antipsychotics are used to reduce medication nonadherence and relapse in schizophrenia-spectrum disorders. The relative effectiveness of long-acting injectable versions of second-generation and older antipsychotics has not been assessed... |
|
|
Maintenance treatment with long-acting injectable antipsychotics: comparing old with new.
JAMA 311(19) , 1973-4, (2014)
|
|
|
Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013) Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who ... |
|
|
Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.
Neurotox. Res. 17(3) , 228-37, (2010) The effects of fish oil supplementation on motor disorders, memory dysfunction, and lipid peroxidation (LP) induced by typical neuroleptics were studied. Wistar rats received a suspension prepared with fish oil containing omega-3 fatty acids, water, and Tween... |
|
|
Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
J. Clin. Psychiatry 74(12) , 1249-55, (2013) Treatment nonadherence in people with schizophrenia is associated with relapse and homelessness. Building on the usefulness of long-acting medication and our work in psychosocial interventions to enhance adherence, we conducted a prospective uncontrolled tria... |
|
|
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.
Am. J. Addict. 15(2) , 166-73, (2006) This retrospective study of patients treated in a ninety-day, inpatient, dual-diagnosis treatment program examined antipsychotic effectiveness in this population using length of stay in treatment and successful program completion as outcome measures. All pati... |
|
|
Reversible cerebral atrophy: a case report and literature review.
Gen. Hosp. Psychiatry 28(5) , 458-62, (2006)
|
|
|
Upregulation of cornichon transcripts in the dorsolateral prefrontal cortex in schizophrenia.
Neuroreport 23(17) , 1031-4, (2012) Schizophrenia has been proposed to be associated with abnormal glutamatergic neurotransmission. The AMPA subtype of glutamate receptors (AMPARs) mediates fast excitatory synaptic transmission in the brain, and their trafficking and function is regulated in pa... |
|
|
Glycine stimulates the release of labeled acetylcholine but not dopamine nor glutamate from superfused rat striatal tissue.
Brain Res. 1168 , 32-7, (2007) Glycine is known as an inhibitory neurotransmitter in the spinal cord and forebrain but its precise role in the forebrain is largely overlooked. This investigation evaluated whether glycine alters acetylcholine, glutamate or dopamine release from striatal tis... |
|
|
The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.
Hum. Psychopharmacol. Clin. Exp. 27(5) , 470-5, (2012) This study was a comparative investigation of the effects on clinical symptoms and cognitive function of switching the treatment of schizophrenia patients from haloperidol decanoate depot to risperidone long-acting injection (RLAI) compared with a control gro... |